LifeX Ventures: Capital and Leadership for Life Science Companies

Strategic Investment for Early-Stage Life Science Innovation

Early-stage life science startups face unique challenges—securing capital, navigating complex regulatory pathways, and building the right leadership team to execute a successful commercialization strategy. At LifeX Ventures, we bridge these gaps by combining venture capital investment with deep, hands-on engagement from experienced industry leaders.

LifeX Ventures Invests in High-Potential Startups Spanning:

The Venture Landscape Has Changed

Today’s early-stage life science startups face longer fundraising timelines, shrinking access to early-stage capital, and heightened expectations for validation before investment. Investors are retreating to later-stage, lower-risk ventures, leaving promising innovations stranded in the “Valley of Death.”

LifeX Ventures exists to change that.

As the investment arm of the LifeX Continuum, we strategically deploy capital into startups that have been pressure-tested across our platform. We combine targeted funding with expert oversight ensuring that the ventures we support are not only scientifically strong but also structurally sound and primed for market success.

Early Formation

Series A/A+

Translational
Research

Follow-On
Funding

Continuum of Programmatic Support & Capital Investment

Engaging Life Science Startups from Translational Research through Series A Funding

A Venture Model Built to De-Risk

We focus on pre-seed and seed rounds, providing catalytic capital to companies with validated concepts, clear market fit, and defined inflection points. Our approach is centered on risk reduction through strategic insight.

Continuum-Driven Diligence

Milestone-Driven Capital Deployment

Strategic Oversight in a Capital-Constrained Era

The LifeX Ventures Investment Process: Purpose-Built for Early-Stage Risk

Our diligence process is thorough, collaborative, and designed for long-term success. Following your initial pitch to our investment team, our investment experts will spend the following weeks reviewing elements of your proposal to ensure strategic fit within the LifeX Ventures model.

LifeX Ventures operates with a deliberate and structured investment process designed for long-term success. Following your initial pitch to our investment team, our investment experts will review your proposal. We work with founders to evaluate:

1
  • Go-To-Market Strategy

2
  • Regulatory & Compliance Roadmap

3
  • Market Potential & Business Model Validation

4
  • Intellectual Property Strategy

5
  • Capitalization Table & Data Room Evaluation

At the end of this process, companies selected for investment receive not just funding, but the hands-on support and connections needed to scale successfully. If a startup is not yet a fit for investment, we provide detailed feedback and direct them to the appropriate LifeX program.

Interested in Pitching Your Company to LifeX Ventures?

If you’re a founder developing a transformative healthcare innovation and want more than just an investment, apply to pitch today.

The LifeX Ventures Team: Strategic Investors.
Purpose-Driven Partners.

LifeX Ventures is led by experienced professionals with deep expertise in investment, commercialization, and life sciences leadership. We understand what it takes to build and scale high-impact companies, and we bring that insight to every partnership.

Focused on Outcomes. Aligned With Mission.

Our team prioritizes ventures that align with LifeX’s mission: bringing impactful, scalable solutions to patients faster. We invest in companies with:

We don’t just invest, we offer structured guidance, hands-on support, and long-term perspective to help startups grow with confidence.

Michael-Young-Headshot

Michael Young

VP Operations, Finance & Administration

Tyler-Berry-Headshot-Image

Tyler Berry

Sr. Investment Analyst

Peter-Vardzel-Headshot-Updated

Peter Vardzel

Jr. Analyst

Matteo-Nee-Headshot

Matteo Nee

Research Analyst

Matthew-Miller-Headshot

Matthew Miller

Venture Advisor

LifeX

John Glicksman

Venture Advisor

Ian-Keller-Headshot

Ian Keller

Investment Analyst Intern

Kevin-Mendelsohn-Headshot

Kevin Mendelsohn

Venture Advisor

Our Portfolio Companies Where Vision Meets Impact

All Industries
HealthTech
Biotech/Pharma
Medical Device

Testimonials What Our Clients Say About LifeX

Michael-Young-Headshot

Michael Young

Vice President Operations, Finance & Administration

Michael currently oversees Operations, Finance, and Strategic Analysis across all LifeX entities and also serves as Treasurer. A seasoned finance executive with over 20 years of experience, he brings deep expertise in financial management, reporting, auditing, strategic planning, forecast modeling, and investment analysis.

His career spans multiple industries—including healthcare, energy, logistics, and software—where he has led high-impact initiatives to optimize financial performance and support organizational growth.

Michael holds a Bachelor of Business Administration in Accounting from Niagara University and a Master of Business Administration in Finance from Le Moyne College. He brings a strong combination of strategic insight and operational rigor to the LifeX leadership team.

Tyler-Berry-Headshot-Image

Tyler Berry

Sr. Investment Analyst

Tyler Berry is a Senior Investment Analyst at LifeX Ventures, where he focuses on identifying and supporting innovative, high-potential companies. He holds a Master’s degree in Finance from the University of Pittsburgh’s Katz Graduate School of Business.

Tyler brings experience in managing mid-cap investment funds and previously founded a fintech startup during his undergraduate studies, demonstrating both his entrepreneurial spirit and commitment to financial innovation.

Passionate about fostering creativity and growth, Tyler leverages his financial expertise and startup mindset to help empower the next generation of groundbreaking ventures.

Peter-Vardzel-Headshot-Updated

Peter Vardzel

Jr. Analyst

Peter Vardzel is a Junior Financial Analyst at LifeX Ventures, where he supports financial modeling, market research, and early-stage investment activities across the portfolio.

He graduated Magna Cum Laude from the University of Pittsburgh with a Bachelor of Science in Finance. During his time at Pitt, Peter was a student-athlete on the Panthers Football team, earning ACC Academic Honor Roll recognition (2021–2024) and contributing to the team’s 2021 ACC Championship and Coastal Division title.

Peter brings the same discipline, drive, and team-oriented mindset from the field to his work in venture finance and is passionate about supporting innovation in the life sciences space.

Matteo-Nee-Headshot

Matteo Nee

Research Analyst

Based in Ontario, Matteo serves as a Venture Consultant for LifeX Ventures, supporting investment pipeline development and capital-raising transaction execution. His work spans sourcing and origination, pitch deck and marketing material review, industry research, and supporting all phases of the transaction process. He also assists the due diligence team with business development and investor engagement activities.

Matteo brings an interdisciplinary background in venture capital, biomedical commercialization, and innovation program design. He began his career in Ohio, where he supported the due diligence and commercialization of dozens of early-stage life science technologies through roles at a life sciences incubator and a Cleveland-based entrepreneurial support organization. He also played a key role in launching a corporate venture and innovation program, as well as a healthcare accelerator.

Now in Canada, Matteo is committed to strengthening biomedical innovation ecosystems across both the U.S. and Canadian markets and helping founders thrive in both environments.

He holds a Master’s degree in Biology with a focus in Entrepreneurial Biotechnology from Case Western Reserve University, and a Bachelor’s degree in Biology from Fujian Agriculture and Forestry University in China.

Matthew-Miller-Headshot

Matthew Miller

Venture Advisor

Matthew is an accomplished HealthTech executive and investor with over 30 years of experience across venture capital, commercialization, and operational leadership. Prior to joining LifeX Ventures, he was Managing Partner at JumpStart Ventures, where he led $140M in early-stage investments focused on MedTech startups.

He spent 18 years on UPMC’s Executive Committee for Technology and Innovation, where he evaluated and helped commercialize internal HealthTech innovations—resulting in multiple successful spinouts and exits to global strategics such as Philips and GE Healthcare.

Matthew has held senior leadership roles at Deloitte Consulting, Alvarez & Marsal, and served as an Operating Partner for Cerberus Capital Management and JW Childs, supporting due diligence, post-investment strategy, and interim executive leadership. He has co-founded and advised startups with exits to Abbott Labs, E*TRADE, and others.
He has served on 20+ HealthTech boards, raised over $130M in venture capital for startups, and been involved in exits exceeding $1.1B.

Matthew proudly served as an officer and decorated combat aviator in the United States Air Force. He holds a BS from Indiana University and an MBA in Finance from the University of Pittsburgh.

LifeX

John Glicksman

Venture Advisor

John has served in multiple leadership roles, including Chief Legal Officer, Chief Compliance Officer, Chief Human Resources Officer, and Board Director for both public and private companies. John also served as a Fund Director for Western Pennsylvania’s first life sciences-focused venture capital fund, where he played a key role in raising capital and supporting emerging ventures.

John has supported companies through all stages of growth, building operational functions from the ground up, managing equity and debt financing, and leading M&A transactions on both the buy- and sell-side. He has also guided businesses through complex restructurings, both in public and private settings.

Earlier in his career, John practiced law in federal and state courts, including appearances before the U.S. Courts of Appeals for the Fourth, Eleventh, and D.C. Circuits. He has also held leadership roles in federal and state trade associations, served as a publicly elected councilman, and taught as an adjunct professor.

Ian-Keller-Headshot

Ian Keller

Investment Analyst Intern at LifeX Ventures

Ian Keller is an Investment Analyst Intern at LifeX Ventures, where he contributes to due diligence, market research, and investment strategy to help support the growth and commercialize of early-stage life science companies.

Ian earned his Master’s degree in Quantitative Economics from the University of Pittsburgh, where he also studied Finance and Statistics during his undergraduate years. With a strong foundation in machine learning and data science, he employs a data-driven approach to his work—translating complex information into clear insights through data storytelling and visualization.

Passionate about health, fitness, and athletics, Ian is motivated by ventures that empower people to live healthier lives. He brings this personal commitment to well-being into his work, helping founders build innovative solutions that improve patient outcomes.

Kevin-Mendelsohn-Headshot

Kevin Mendelsohn

Venture Advisor

Kevin Mendelsohn is an experienced medtech executive with a background spanning investment, management, and commercialization of early-stage technologies. He was a founding member of the investment team and served as a Venture Partner at JumpStart Inc., a Northeast Ohio venture development firm supporting regional technology companies through entrepreneurial services, corporate innovation strategy, and early-stage capital.

Kevin was part of the executive leadership team at CardioInsight Technologies, a non-invasive electrocardiographic mapping company focused on treating atrial fibrillation, which was acquired by Medtronic. He also held leadership roles in product development and finance at Athersys, a publicly traded biopharmaceutical company developing novel stem cell, small molecule, and protein-based therapies.

Kevin earned an MBA from Case Western Reserve University’s Weatherhead School of Management and holds a BS in Zoology and Economics from Miami University.